







an Open Access Journal by MDPI

# Novel Biomarkers in Leukemia: From Benchtop to Bedside

Guest Editors:

### Dr. Peppino Mirabelli

SYNLAB IRCCS SDN, via E. Gianturco n. 113, 80143 Napoli, Italy

### Dr. Luigi Vitagliano

Institute of Biostructures and Bioimaging, CNR, Via Pietro Castellino n. 111, 80131 Napoli, Italy

#### Dr. Giovanni Smaldone

SYNLAB IRCCS SDN, via E. Gianturco n. 113, 80143 Napoli, Italy

Deadline for manuscript submissions:

closed (30 September 2022)

# **Message from the Guest Editors**

Leukemia is a highly heterogeneous disease caused by the malignant transformation of undifferentiated myeloid/lymphoid hematopoietic progenitors.

The identification of new leukemia biomarkers represents a crucial step for diagnosis, prognosis and treatment. Currently, cytogenetic markers are widely used for diagnosis and patient stratification. However, the situation is rapidly changing due to the application of other methodologies based on the characterization of disease-causing mutations and of epigenetic and proteomic profiles. In this Special Issue, we are inviting the submission of reviews and novel research results in the field. In this Special Issue, special attention will be given to manuscripts highlighting the interplay between the search for new biomarkers and the elucidation of the molecular basis of this widespread disease. Moreover, articles dealing with identifying surface antigens in leukemia to plan novel CART-mediated cellular therapy will be welcome.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

# **Message from the Editor-in-Chief**

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*)

#### **Contact Us**